Human parainfluenza viruses Pre-fusion glycoprotein F0, His Tag (MALS verified)

사용자 리뷰
제품 번호/규격
가격
수량
PR0-H52H3-50ug
$465.00
PR0-H52H3-500ug
$2885.00
ETA of in-stock products:2 business days
총 항목 수 제품 금액$ 0

제품 세부정보

  • Synonyms

    Prefusion glycoprotein F0/pre-F protein (RSV)

  • Source

    Human parainfluenza viruses Pre-fusion glycoprotein F0, His Tag (PR0-H52H3) is expressed from human 293 cells (HEK293). It contains AA Gln 19 - Thr 493 (Accession # AGW51052.1).

    Predicted N-terminus: Gln 19

    Request for sequence
  • Molecular Characterization

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 57.8 kDa. The protein migrates as 58-65 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

    Within the expressed region, several mutations were introduced to optimize the protein expression and stability.

    The protein is designed as a trimer.

  • Endotoxin

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • Purity

    >95% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in 0.1 M Sodium citrate, pH5.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Shipping and Storage

    This product is shipped at ambient temperature.

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

고객님도 확인한 상품

데이터 표시

  • SDS-PAGE

    Prefusion glycoprotein F0/pre-F protein (RSV) SDS-PAGE

    Human parainfluenza viruses Pre-fusion glycoprotein F0, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

  • SEC-MALS

    Prefusion glycoprotein F0/pre-F protein (RSV) SEC-MALS

    The purity of Human parainfluenza viruses Pre-fusion glycoprotein F0, His Tag (Cat. No. PR0-H52H3) is more than 95% and the molecular weight of this protein is around 200-230 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     Prefusion glycoprotein F0/pre-F protein (RSV) ELISA

    Immobilized Human parainfluenza viruses Pre-fusion glycoprotein F0, His Tag (Cat. No. PR0-H52H3) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-Human parainfluenza viruses Pre-fusion glycoprotein F0 Antibody, Human IgG1 (15A10) (Cat. No. HPV-MY2325) with a linear range of 0.04-2 ng/mL (Routinely tested).

    Protocol

사용자 리뷰
댓글 남기기

FAQ

  • Product

    What do “pre” and “post” refer to in the names of viral proteins?

    In virology, “pre” refers to the conformation of a viral surface glycoprotein before fusion with the host cell membrane, while “post” refers to the conformation after membrane fusion and entry into the host cell. Both are naturally occurring states in the viral life cycle. Because the “pre” conformation represents a critical stage before viral entry, antibodies designed against this state often exhibit stronger neutralizing activity and are therefore more effective in preventing infection.

배경 소개

Human respiratory syncytial virus (HRSV) is the most common etiological agent of acute lower respiratory tract disease in infants and can cause repeated infections throughout life. The RSV fusion glycoprotein (RSV F) is the principal target of RSV neutralizing antibodies in human sera. The RSV F is a type I viral fusion protein synthesized as inactive, single-chain polypeptides that assemble into trimers. RSV F fuses the viral and host cell membranes by irreversible protein refolding from the labile prefusion conformation to the stable post-fusion conformation. Both states exhibit epitopes targeted by neutralizing antibodies, and post-fusion RSV F is being developed as a vaccine candidate.

프론티어 진행

 
연락하기
신약 후보물질 라이선싱
더 많이 알아보기
  • 기본 제품 정보
  • 제품 세부정보
  • 고객님도 확인한 상품
  • 데이터 표시
  • 사용자 리뷰
  • FAQ
  • 배경
문의하기

전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521

주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호